Orphan drug discoveries & academic centers of excellence at World Orphan Drug Congress USA

Hans Schikan of Prosensa on biotech partnerships at World Orphan Drug Congress USA 2013Подробнее

The NIH on infrastructure start-up for a global patient registry at World Orphan Drug Congress USAПодробнее

Rare disease and orphan drugs: industry executives at World Orphan Drug Congress USAПодробнее

Orphan drug discoveries & academic centers of excellence at World Orphan Drug Congress USAПодробнее

Andrew Callos of Pfizer on building a rare disease franchise at World Orphan Drug Congress USA 2013Подробнее

World Orphan Drug Congress USA 2013 - who should attendПодробнее

World Orphan Drug Congress - who should attend?Подробнее

Anne Pariser of the FDA on natural history studies in rare disease at World Orphan Drug Congress USAПодробнее

Andrew Callos of Pfizer on sustainable business in rare disease at World Orphan Drug Congress USAПодробнее

The World Orphan Drug CongressПодробнее

World Orphan Drug Congress (2019)Подробнее

The Success of the Orphan Drug ActПодробнее

Enobia & LapidusData on history and epidemiology in rare disease at World Orphan Drug Congress USAПодробнее

world orphan drug congress usa 2013- pitch and partner / expoПодробнее

Rare disease clinical trials with Shire, Novartis and more at World Orphan Drug Congress USA 2013Подробнее

Orphan Drug Congress April 2013: Part 3, Trial ImplementationПодробнее

Orphan Drugs Conquering Rare Diseases One-by-OneПодробнее

Orphan Drug Coverage LimitsПодробнее

Pfizer's Rare Disease Unit - Advancing the Discovery, Development, and Availability of Orphan DrugsПодробнее

World Orphan Drug Congress 2014Подробнее